V
Valérie Fraix
Researcher at University of Grenoble
Publications - 149
Citations - 12361
Valérie Fraix is an academic researcher from University of Grenoble. The author has contributed to research in topics: Deep brain stimulation & Parkinson's disease. The author has an hindex of 46, co-authored 132 publications receiving 11218 citations. Previous affiliations of Valérie Fraix include Centre Hospitalier Universitaire de Grenoble & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease.
Paul Krack,Alina Batir,Nadège Van Blercom,Stephan Chabardes,Valérie Fraix,Claire Ardouin,Adnan Koudsie,Patricia Limousin,Abdelhamid Benazzouz,Jean François LeBas,Alim-Louis Benabid,Pierre Pollak +11 more
TL;DR: There was no control group, but worsening of akinesia, speech, postural stability, freezing of gait, and cognitive function between the first and the fifth year is consistent with the natural history of Parkinson's disease.
Journal ArticleDOI
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up
M.C. Rodríguez-Oroz,Jose A. Obeso,Anthony E. Lang,J. L. Houeto,Pierre Pollak,Stig Rehncrona,Jaume Kulisevsky,Alberto Albanese,Jens Volkmann,Marwan Hariz,Niall Quinn,Johannes D. Speelman,Jorge Guridi,I Zamarbide,Alexandre Gironell,Joan Molet,Berta Pascual-Sedano,Bernard Pidoux,A M Bonnet,Yves Agid,Jing Xie,Alim-Louis Benabid,Andres M. Lozano,Jean A. Saint-Cyr,Luigi Romito,Maria Fiorella Contarino,Massimo Scerrati,Valérie Fraix,N. Van Blercom +28 more
TL;DR: This first multicentre study assessing the long-term efficacy of either STN or GPi stimulation shows a significant and substantial clinically important therapeutic benefit for at least 3-4 years in a large cohort of patients with severe Parkinson's disease.
Journal ArticleDOI
Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease
Aurélie Funkiewiez,Claire Ardouin,E. Caputo,Paul Krack,Valérie Fraix,Hélène Klinger,Stephan Chabardes,Kelly D. Foote,Alim-Louis Benabid,Pierre Pollak +9 more
TL;DR: Comparing baseline, one year, and three year postoperative assessments, STN stimulation did not lead to global cognitive deterioration, and depression improved whereas apathy and thought disorders worsened.
Journal ArticleDOI
Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation
Stéphane Thobois,Claire Ardouin,Claire Ardouin,Eugénie Lhommée,Eugénie Lhommée,Hélène Klinger,Hélène Klinger,Christelle Lagrange,Christelle Lagrange,Jing Xie,Jing Xie,Valérie Fraix,Valérie Fraix,Maria Clara Coelho Braga,Rachid Hassani,Andrea Kistner,Andrea Kistner,Alexandra Juphard,Eric Seigneuret,Eric Seigneuret,Stephan Chabardes,Stephan Chabardes,Patrick Mertens,Gustavo Polo,Anthonin Reilhac,Nicolas Costes,Didier Lebars,Marc Savasta,Léon Tremblay,Jean-Louis Quesada,Jean-Luc Bosson,Alim-Louis Benabid,Emmanuel Broussolle,Emmanuel Broussolle,Pierre Pollak,Pierre Pollak,Paul Krack,Paul Krack +37 more
TL;DR: A prospective study of the occurrence of apathy and associated symptoms, predictors and mechanisms in the year following subthalamic stimulation in patients with Parkinson's disease, finding non-motor fluctuations are related to mesolimbic dopaminergic denervation.
Journal ArticleDOI
Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease
M.U. Ferraye,M.U. Ferraye,Bettina Debû,Bettina Debû,Valérie Fraix,Valérie Fraix,Laurent Goetz,Laurent Goetz,Claire Ardouin,Jérôme Yelnik,C. Henry-Lagrange,C. Henry-Lagrange,Eric Seigneuret,Brigitte Piallat,Brigitte Piallat,Paul Krack,Paul Krack,J.F. Le Bas,J.F. Le Bas,Alim-Louis Benabid,Alim-Louis Benabid,Stephan Chabardes,Stephan Chabardes,Pierre Pollak,Pierre Pollak +24 more
TL;DR: Although freezing of gait can be improved by low-frequency electrical stimulation of the pedunculopontine nucleus area in some patients with Parkinson's disease, the overall results are disappointing compared to the high levels of expectation raised by previous open label studies.